Table 4.
Examples of current immunomodulatory antibodies targeting T cells
| Receptor | Ligand | Antibody | Stage of development |
|---|---|---|---|
| Costimulation molecules | |||
| 4-1BB | 4-1BBL | Urelumab | Phase II |
| Utomilumab | Phase I | ||
| ADG106 | Phase I | ||
| OX40 | OX40L | MEDI6469 | Phase II |
| PF-04518600 | Phase II | ||
| GSK3174998 | Phase I | ||
| BMS 986178 | Phase I | ||
| MOXR0916 | Phase I | ||
| INBRX-106 | Phase I | ||
| BGB-A445 | Phase I | ||
| CD27 | CD70 | Varlilumab | Phase II |
| GITR | GITRL | TRX518 | Phase II |
| BMS-986156 | Phase II | ||
| INCAGN01876 | Phase II | ||
| GWN323 | Phase I | ||
| MEDI1873 | Phase I | ||
| OMP-336B11 | Phase I | ||
| MK-4166 | Phase I | ||
| ICOS | ICOSL | GSK3359609 | Phase II |
| Vopratelimab | Phase I/II | ||
| KY1044 | Phase I/II | ||
| TNFRSF25 | TL1A | Preclinical | |
| Inhibitory molecules | |||
| PD1 | PD-L1/PD-L2 | Pembrolizumab | Approved |
| Nivolumab | Approved | ||
| Cemiplimab | Approved | ||
| Sintilimab | Approved | ||
| JS001 | Approved | ||
| Camrelizumab | Phase III | ||
| BCD-100 | Phase III | ||
| Tislelizumab | Phase III | ||
| Spartalizumab | Phase III | ||
| Dostarlimab | Phase III | ||
| REGN2810 | Phase III | ||
| CTLA4 | CD80/CD86 | Ipilimumab | FDA approved |
| Tremelimumab | Phase III | ||
| LAG3 | MHC-II | Relatlimab | Phase II |
| LAG525 | Phase II | ||
| REGN3767 | Phase I | ||
| TSR-033 | Phase I | ||
| Sym022 | Phase I | ||
| TIM3 | Phosphatidylserine | TSR-022 | Phase II |
| BGB-A425 | Phase I/II | ||
| MBG453 | Phase I/II | ||
| LY3321367 | Phase I | ||
| Sym023 | Phase I | ||